These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20970245)

  • 1. Is tumor response important for renal carcinoma?
    Inman BA; George DJ
    Eur Urol; 2011 Jan; 59(1):16-7. PubMed ID: 20970245
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: E. Jason Abel, Stephen H. Culp, Nizar M. Tannir, et al. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 2011;59:10-5.
    Ozcan MF; Canda AE; Dizdar O; Altinova S; Akbulut Z; Balbay MD
    Eur Urol; 2011 Jun; 59(6):e34. PubMed ID: 21398023
    [No Abstract]   [Full Text] [Related]  

  • 3. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Editorial comment.
    Singer EA; Srinivasan R; Bratslavsky G
    J Urol; 2011 Jan; 185(1):66. PubMed ID: 21074200
    [No Abstract]   [Full Text] [Related]  

  • 5. [Biomarker for molecular targeting therapy against renal cell carcinoma].
    Mizuno R; Oya M
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):39-42. PubMed ID: 22454982
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use.
    Kirkali Z
    BJU Int; 2011 Jun; 107(11):1722-32. PubMed ID: 21251188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
    Kirkwood JM; Tarhini AA
    J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
    [No Abstract]   [Full Text] [Related]  

  • 8. [Systemic therapy for metastatic renal cell carcinoma].
    Kramer MW; Steffens S; von Klot C; Merseburger AS; Kuczyk MA
    Aktuelle Urol; 2012 Jul; 43(4):265-8. PubMed ID: 22869498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Blute ML
    Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Giannarini G; Autorino R
    Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma.
    Procopio G; Verzoni E; de Braud F
    Oncology; 2013; 84(1):39-42. PubMed ID: 23076302
    [No Abstract]   [Full Text] [Related]  

  • 13. [Molecular targeted therapy for advanced renal cell carcinoma].
    Kanayama H
    Gan To Kagaku Ryoho; 2010 Jul; 37(7):1208-13. PubMed ID: 20647700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 15. Temsirolimus (Torisel) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
    [No Abstract]   [Full Text] [Related]  

  • 16. Retrospective analyses of patient characteristics having predictive impact on survival under everolimus.
    Seidel C; Fenner M; Reuter C; Merseburger AS; Ganser A; Grünwald V
    Onkologie; 2011; 34(3):111-4. PubMed ID: 21358215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
    Bellmunt J; Ribas A
    Eur Urol; 2009 Jun; 55(6):1342-3. PubMed ID: 19201525
    [No Abstract]   [Full Text] [Related]  

  • 18. Editorial comment on: Vaccine therapy in patients with renal cell carcinoma.
    Clark PE
    Eur Urol; 2009 Jun; 55(6):1343-4. PubMed ID: 19201523
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug now immediately available in Germany].
    Aktuelle Urol; 2006 Sep; 37(5 Suppl):18-9. PubMed ID: 23646396
    [No Abstract]   [Full Text] [Related]  

  • 20. Medullary renal cell carcinoma and response to therapy with bortezomib.
    Ronnen EA; Kondagunta GV; Motzer RJ
    J Clin Oncol; 2006 Mar; 24(9):e14. PubMed ID: 16549825
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.